长效注射纳曲酮诱导:门诊阿片脱毒随机试验比较纳曲酮与丁丙诺啡
该随机试验将150名阿片依赖成人按2:1分配至纳曲酮辅助或丁丙诺啡辅助门诊脱毒方案,随后注射缓释纳曲酮(XR-纳曲酮)。纳曲酮辅助组成功诱导至XR-纳曲酮的比例为56.1%,显著高于丁丙诺啡辅助组的32.7%;第5周接受第二次注射的比例分别为50.0%和26.9%。结论认为低剂量纳曲酮联合单日丁丙诺啡及辅助非阿片药物安全有效,为XR-纳曲酮诱导提供了有前景的替代策略。
要点
- 纳曲酮辅助脱毒组成功诱导至XR-纳曲酮的比例显著高于丁丙诺啡辅助组(56.1% vs 32.7%)。
- 第5周接受第二次XR-纳曲酮注射的比例纳曲酮组为50.0%,丁丙诺啡组为26.9%。
- 低剂量纳曲酮联合单日丁丙诺啡及辅助非阿片药物安全、有效且耐受性良好。
核心结论
- 低剂量纳曲酮联合单日丁丙诺啡及辅助非阿片药物可安全有效地将阿片依赖成人诱导至XR-纳曲酮。
- 该策略为门诊阿片脱毒诱导XR-纳曲酮提供了优于丁丙诺啡渐减方案的有前景替代。
研究设计与样本
- 随机试验将150名阿片依赖成人按2:1分配至纳曲酮辅助脱毒或丁丙诺啡辅助脱毒门诊方案,随后注射XR-纳曲酮。
- 纳曲酮辅助脱毒持续7天,包括单日丁丙诺啡后递增口服纳曲酮剂量,并联合可乐定及其他辅助药物。
- 丁丙诺啡辅助脱毒包括7天丁丙诺啡渐减,随后延迟一周再给予XR-纳曲酮,符合官方处方信息。
- 两组均接受关注用药依从性的行为治疗并接受第二剂XR-纳曲酮。
主要发现
- 纳曲酮辅助脱毒组成功诱导至XR-纳曲酮的比例为56.1%,丁丙诺啡辅助脱毒组为32.7%,差异显著。
- 纳曲酮辅助脱毒组第5周接受第二次注射的比例为50.0%,丁丙诺啡辅助脱毒组为26.9%。
- 两种模型均对主要阿片使用类型、阿片给药途径及基线吗啡当量进行了调整。
关键数值与推荐
- 成功诱导至XR-纳曲酮:纳曲酮辅助脱毒组56.1% vs 丁丙诺啡辅助脱毒组32.7%。
- 第5周接受第二次XR-纳曲酮注射:纳曲酮辅助脱毒组50.0% vs 丁丙诺啡辅助脱毒组26.9%。
临床怎么用
- 对阿片依赖成人启动XR-纳曲酮时,可考虑低剂量纳曲酮联合单日丁丙诺啡及辅助非阿片药物的门诊脱毒方案。
- 该方案可能降低诱导期脱落与复发风险,优于丁丙诺啡渐减后延迟给药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone. METHOD: Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone. Naltrexone-assisted detoxification lasted 7 days and included a single day of buprenorphine followed by ascending doses of oral naltrexone along with clonidine and other adjunctive medications. Buprenorphine-assisted detoxification included a 7-day buprenorphine taper followed by a week-long delay before administration of XR-naltrexone, consistent with official prescribing information for XR-naltrexone. Participants from both groups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone. RESULTS: Compared with participants in the buprenorphine-assisted detoxification condition, participants assigned to naltrexone-assisted detoxification were significantly more likely to be successfully inducted to XR-naltrexone (56.1% compared with 32.7%) and to receive the second injection at week 5 (50.0% compared with 26.9%). Both models adjusted for primary type of opioid use, route of opioid administration, and morphine equivalents at baseline. CONCLUSIONS: These results demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid dependence to XR-naltrexone. This strategy offers a promising alternative to the high rates of attrition and relapse currently observed with agonist tapers in both inpatient and outpatient settings.
引用
- Sullivan M, Bisaga A, Pavlicova M, et al. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. Am J Psychiatry. 2017. PMID: 28068780. doi:10.1176/appi.ajp.2016.16050548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。